Denosumab clinical trials
Also written Prolia, Xgeva, AMG 162 and CT-P41.
Its developmentBy 13 companies, company by company78 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.Includes 5 studies of QL1206.
How each study uses Denosumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Denosumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 Jun 2010 · PROLIA · BLA 125320 (FDA, Drugs@FDA)
- European Union
- 26 May 2010 · Prolia · EMEA/H/C/001120 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
205 studies that test it; most in 2019 (22); 2 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 1 |
| 2006 | 11 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 11 |
| 2013 | 9 |
| 2014 | 12 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 20 |
| 2018 | 14 |
| 2019 | 22 |
| 2020 | 12 |
| 2021 | 13 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 88 · Other 119
Amgen (55) · Massachusetts General Hospital (8) · Shenzhen People's Hospital (7) · Martin Blomberg Jensen (5) · Mabwell (Shanghai) Bioscience Co., Ltd. (5) · Qilu Pharmaceutical Co., Ltd. (5) · GlaxoSmithKline (5) · Celltrion (3)
Often tested with
Tested in the same studies.
Zoledronic Acid (11) · Teriparatide (5) · Romosozumab (4) · Alendronate (4) · Pamidronate (2) · Letrozole (1) · TVB-009 (1) · Calcium (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Denosumab is the comparator. A study of two new drugs counts under both.
- 2Narlumosbart · RenJi Hospital, Shanghai JMT-Bio Inc. · next primary completion Jun 2028
Reaching primary completion within a year · 11, 2 in phase 3
Studies that test Denosumab, phase 3 first.
- Jan 2027A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Jul 2027Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationPhase 3 · Alliance for Clinical Trials in Oncology
- Jan 2027Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaPhase 4 · Amgen
- Feb 2027Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsPhase 2 · Australian and New Zealand Intensive Care Research Centre
- Mar 2027Romosozumab/Denosumab Study for Premenopausal IOPPhase 2 · Columbia University
- Mar 2027The Effect of Denosumab on Muscle and Strength and Insulin SensitivityPhase 4 · Aarhus University Hospital
- Apr 2027RANK-ligand Inhibition to Combat Sarcopenia With Underlying OsteoporosisPhase 4 · Prince of Wales Hospital, Shatin, Hong Kong
- Apr 2027A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland ChinaPhase 4 · Amgen
- Jul 2027Markers of Osteoporosis in Cystic FibrosisPhase 4 · University of Texas Southwestern Medical Center
- Oct 2027Anabolic Therapy in Postmenopausal OsteoporosisPhase 4 · Massachusetts General Hospital
Studies
Open first, then newest update. How each study uses Denosumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 207
- Denosumab for Type 1 DiabetesRecruitingPhase 1/2City of Hope Medical CenterNCT06524960Written as DenosumabHow we know
- The DENOCHARCOT TrialRecruitingPhase 3Ole Lander SvendsenNCT04547348Written as Denosumab InjectionHow we know
- Preserving Geriatric Muscle With an Osteoporosis MedicationRecruitingPhase 4Chrissy KistlerNCT06118905Written as Denosumab 60 MG/MLHow we know
- RANK-ligand Inhibition to Combat Sarcopenia With Underlying OsteoporosisRecruitingPhase 4Prince of Wales Hospital, Shatin, Hong KongNCT06643780Written as DenosumabHow we know
- RANKL Inhibition to Combat Sarcopenia in Hip Fracture PatientsNot yet recruitingPhase 3Prince of Wales Hospital, Shatin, Hong KongNCT07056478Written as Denosumab (Prolia)How we know
- Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDNot yet recruitingPhase 4Sahlgrenska University HospitalNCT07772609Written as DenosumabHow we know
- Markers of Osteoporosis in Cystic FibrosisRecruitingPhase 4University of Texas Southwestern Medical CenterNCT03921060Written as DenosumabHow we know
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsRecruitingPhase 2Australian and New Zealand Intensive Care Research CentreNCT04608630Written as Denosumab 60 MG/MLHow we know
- Romosozumab and Denosumab, Alone or Combined, in Postmenopausal OsteoporosisRecruitingPhase 4National Taiwan University HospitalNCT07283887Written as DenosumabHow we know
- The Effect of Denosumab on Muscle and Strength and Insulin SensitivityRecruitingPhase 4Aarhus University HospitalNCT07271771Written as DenosumabHow we know
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®RecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07062978Written as QL1206How we know
- DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)RecruitingPhase 4Natasha Appelman-DijkstraNCT05966064Written as Denosumab 120 Mg/1.7 Ml InjHow we know
- Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility FracturesNot yet recruitingPhase 4Marmara UniversityNCT06720350Written as Romosozumab and Denosumab Combination TherapyHow we know
- Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related OutcomesRecruitingPhase 3Wuhan Union Hospital, ChinaNCT06154707Written as Denosumab InjectionHow we know
- Denosumab Biosimilar Injection in Post Menopausal Women With OsteoporosisRecruitingPhase 3Lambda Therapeutic Research Ltd.NCT05419427Written as DenosumabHow we know
- Denosumab Treatment in CKD Patients at High Risk of FractureRecruitingNot applicableCapital Medical UniversityNCT05692297Written as DenosumabHow we know
- Muscle Impact of Treating OsteoporosisCompletedPhase 4Nami Safai HaeriNCT05666310Written as DenosumabHow we know
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksTerminatedPhase 3Swiss Cancer InstituteNCT02051218Written as Denosumab (reduced dosing)How we know
- NT-NOA - Novel Treatment of Some Men With Non-Obstructive AzoospermiaCompletedPhase 1/2Martin Blomberg JensenNCT06706414Written as Denosumab (Prolia)How we know
- RANKL Inhibition and Mammographic Breast DensityActive, not recruitingPhase 2Washington University School of MedicineNCT04067726Written as DenosumabHow we know
See all 207 studies that test Denosumab →
Given beside what is tested · 18 — Denosumab is usual care or a partner of the new treatment
- Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 YearsNot yet recruitingPhase 4Tuen Mun HospitalNCT07757373Written as DenosumabHow we know
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefractureRecruitingNot applicablePeking Union Medical College HospitalNCT05866029Written as DenosumabHow we know
- ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian CancersRecruitingPhase 1National University Hospital, SingaporeNCT06513624Written as Denosumab / Zoledronic AcidHow we know
- An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06749886Written as DenosumabHow we know
- Effect of Alfacalcidol on Muscle Function in Osteoporosis PatientsNot yet recruitingPhase 4Yonsei UniversityNCT06272227Written as DenosumabHow we know
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneActive, not recruitingPhase 4Hospital for Special Surgery, New YorkNCT04467983Written as Denosumab InjectionHow we know
- Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 MonthsCompletedPhase 4Tuen Mun HospitalNCT06472050Written as DenosumabHow we know
- Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)CompletedPhase 4Xi'an Honghui HospitalNCT05884372Written as DenosumabHow we know
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCIActive, not recruitingPhase 4James J. Peters Veterans Affairs Medical CenterNCT05101018Written as DenosumabHow we know
- Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®WithdrawnPhase 3Xentria, Inc.NCT06504966Written as Prolia®How we know
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedPhase 2Redx Pharma LtdNCT04907539Written as DenosumabHow we know
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)CompletedPhase 2Redx Pharma LtdNCT04907851Written as DenosumabHow we know
- A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With OsteoporosisCompletedPhase 3Samsung Bioepis Co., Ltd.NCT04664959Written as Prolia® (Denosumab)How we know
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisCompletedPhase 3AmgenNCT01575834Written as DenosumabHow we know
- Comparative Antiresorptive Efficacy Discontinuation of DenosumabActive, not recruitingPhase 4Massachusetts General HospitalNCT03623633Written as denosumabHow we know
- Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid TumorsStatus unknownPhase 3Luye Pharma Group Ltd.NCT04859569Written as Xgeva®How we know
- Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasesTerminatedPhase 2University of HawaiiNCT02758132Written as DenosumabHow we know
- Effect of RANKL Inhibition on UV-induced ImmunosuppressionCompletedPhase 1Innovaderm Research Inc.NCT01978483Written as DenosumabHow we know
As the comparator · 30 — what is tested is compared with Denosumab
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisRecruitingPhase 1/2Washington University School of MedicineNCT06374459Written as DenosumabHow we know
- Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis PatientsRecruitingPhase 4National Taiwan University HospitalNCT06938152Written as Romosozumab followed by DenosumabHow we know
- Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingPhase 2Tongji HospitalNCT07537972Written as DenosumabHow we know
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone DiseaseNot yet recruitingPhase 3RenJi HospitalNCT06314698Written as DenosumabHow we know
- A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of BoneNot yet recruitingPhase 3Shanghai JMT-Bio Inc.NCT05813665Written as DenosumabHow we know
- A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous InjectionCompletedPhase 1Shandong Boan Biotechnology Co., LtdNCT06095427Written as US-Prolia (Denosumab)How we know
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCICompletedPhase 2VA Office of Research and DevelopmentNCT04232657Written as DenosumabHow we know
- A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®CompletedPhase 3Enzene Biosciences Ltd.NCT05405725Written as ProliaHow we know
- Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With OsteoporosisCompletedPhase 3Biocon Biologics UK LtdNCT05345691Written as Prolia®How we know
- Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®CompletedPhase 1Xentria, Inc.NCT06310824Written as EU-Prolia®How we know
- Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBONDCompletedPhase 3Alvotech Swiss AGNCT05395091Written as DenosumabHow we know
- AVT03 With Xgeva in Healthy Male SubjectsCompletedPhase 1Alvotech Swiss AGNCT05876949Written as DenosumabHow we know
- A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.CompletedPhase 3mAbxience Research S.L.NCT05338086Written as EU-ProliaHow we know
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With OsteoporosisCompletedPhase 3Fresenius Kabi SwissBioSim GmbHNCT04934072Written as US-licensed Prolia (Amgen)How we know
- A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced XgevaCompletedPhase 1mAbxience Research S.L.NCT05299073Written as US-sourced XgevaHow we know
- Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy VolunteersCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT06361355Written as ProliaHow we know
- Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal OsteoporosisCompletedPhase 3Gedeon Richter Plc.NCT05087030Written as Prolia®How we know
- AVT03 With Prolia in Healthy Male SubjectsCompletedPhase 1Alvotech Swiss AGNCT05126784Written as ProliaHow we know
- Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerSCompletedPhase 1Biocon Biologics UK LtdNCT05323708Written as Prolia®How we know
- Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy VolunteersWithdrawnPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT05808673Written as Xgeva®How we know
Showing 20 of 30.
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- Muscle Impact of Treating OsteoporosisOct 27, 2026NCT05666310
Stopped1
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksTerminatedOct 23, 2026NCT02051218
Codes
What other systems call Denosumab · ClinicalTrials.gg INT006582
- MeSH (NLM) D000069448DenosumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4EQZ6YO2HIDENOSUMABConfirmed FDA, NLM, Wikidata
- RxNorm 993449Confirmed FDA, Wikidata
- Wikidata Q408283denosumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61313DenosumabOne source FDA
- DrugBank DB06643One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069448 | Denosumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4EQZ6YO2HI | DENOSUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 993449 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408283 | denosumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61313 | Denosumab | One source FDA |
| DrugBank | DB06643 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.